Brief: Alembic Pharmaceuticals Receives USFDA Tentative Approval For Larotrectinib Capsules 25 Mg And 100 Mg
11/06/2026 08:06
BRIEF-Alembic Pharmaceuticals Receives USFDA Tentative Approval For Larotrectinib Capsules 25 Mg And 100 Mg June 11 (Reuters) - Alembic Pharmaceuticals Ltd ALEM.NS:
ALEMBIC PHARMACEUTICALS - RECEIVES USFDA TENTATIVE APPROVAL FOR LAROTRECTINIB CAPSULES 25 MG AND 100 MG
Source text: ID:nBSE6wNXFh
Further company coverage: ALEM.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alembic Pharmaceuticals
See all newsIndia's Alembic Pharma rises after US FDA approves herpesvirus drug
Brief: Alembic Pharmaceuticals Receives USFDA Final Approval For Valganciclovir Oral Solution 50 Mg/Ml
Brief: Alembic Pharmaceuticals Completes USFDA Bioequivalence Inspection At Vadodara With No Observations
India's Alembic Pharma gains as brokerages optimistic after quarterly profit rise
India's Alembic Pharma posts quarterly profit rise on strong generics demand